Post-earnings recap
Reported
Mon, Aug 3, 2026
EPS actual
$-1.01
EPS est.
$0.30
EPS surprise
-436.67%
1-day move
+3.07%
Supernus Pharmaceuticals reported a significant earnings miss with an EPS of -$1.01 compared to the expected $0.51. Despite this disappointing result, the stock rose by 3.07%, indicating that investors may be reacting to other factors or future potential rather than the current earnings performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.01 | $0.51 | -436.67% |
| Revenue | — | $205M | — |
No transcript is on record, and the analysis is based on numerical results only.
Supernus Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing innovative therapies for neurological and psychiatric conditions. With a market cap of $3 billion, its performance is closely tied to the pharmaceutical industry's trends and the demand for mental health treatments.
Last quarter
In Q1 2026, Supernus reported an EPS of -$0.04, significantly missing the expected $0.14. This marked a continuation of disappointing earnings results.
EPS beat streak
0Q
EPS beat rate
25%
Avg EPS surprise
-137.83%
Avg 1-day reaction
+1.96%
Analysts expect Supernus to report an EPS of $0.51 and revenue of $205 million for Q2 2026, reflecting cautious optimism after recent earnings misses.
Bull case
If Supernus can exceed EPS estimates and show strong revenue growth, it could signal a turnaround, boosting investor confidence.
Bear case
Continued earnings misses or weak guidance could lead to further declines in stock price, as investors may lose faith in the company's recovery.
Key metrics to watch
Earnings Per Share (EPS)
$0.51EPS is a key indicator of a company's profitability and is closely watched by investors.
Revenue
$205MRevenue gives insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Supernus achieve an EPS of at least $0.51?
This specific EPS target is crucial for restoring investor confidence after recent misses.
Q2
What are the revenue projections for the upcoming quarters?
Revenue performance will indicate market demand and the effectiveness of Supernus's product strategies.
—
Est. EPS
$1.16
Est. Rev
$1.3B
Impl. Move
±8.0%
Why consensus could be wrong
The consensus may underestimate the potential for a rebound in EPS as recent product launches gain traction in the market.
Supporting evidence
Despite recent misses, Supernus has a history of surprising positively when expectations are low.
Options pricing suggests a larger move than historical averages, indicating potential for a significant shift.
The company's focus on neurological treatments may be timely given the increasing awareness of mental health issues.
Key risk
If revenue exceeds $210 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is debating whether Supernus can turn around its recent performance and meet or exceed expectations.
Bull confirmed if
An EPS of $0.55 or higher would confirm the bull case, suggesting a strong recovery.
Bear confirmed if
An EPS below $0.44 would support the bear case, indicating ongoing struggles.
What the market is pricing for the move.
Implied Move
±19.16%
Historical Avg
±2.0%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.
Options are pricing ±19.2% while SUPN has averaged ±2.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
35.3%
Smart-money positioning from the most recent 13F filings.
Institutional
106.24%
of float
Insider
4.32%
of float
Holders
454
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
9,350,046 sh · $402.5M
16.06%
6.3%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Supernus beats expectations, history suggests a potential stock increase of around +1.10%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may react mildly, reflecting uncertainty in management's commentary.
Miss
Should Supernus miss again, the average historical reaction indicates a potential decline of around +1.83%, raising concerns about its future.
The lines on the call that would change the story.
Millennium Management Llc
3,853,212 sh · $165.9M
6.62%
16.2%
Vanguard Portfolio Management LLC
3,305,429 sh · $142.3M
5.68%
2.1%
Armistice Capital, LLC
2,646,201 sh · $113.9M
4.54%
39.6%
Vanguard Capital Management LLC
2,516,721 sh · $108.3M
4.32%
2.0%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.